Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. (KPTI): 12 pipeline candidates · 9 upcoming catalysts · ~13 mo cash runway · 14 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
13.4 months
D/E -1.49 · 0% dilution
Lead: Phase 3
12 candidates
9 upcoming, next in ~562d
0 buys · 17 sells (180d)
A transparent, data-derived signal for Karyopharm Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$213.0M
Cash
$91.2M
Quarterly Burn
$22.7M
Runway
13.4 mo
Revenue
$35.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| belantamab mafodotin | Phase 1/Phase 2 |
| bendamustine | Phase 1/Phase 2 |
| daratumumab | Phase 1/Phase 2 |
| elotuzumab | Phase 1/Phase 2 |
| eltanexor | Phase 3 |
| ixazomib | Phase 1/Phase 2 |
| mezigdomide | Phase 1/Phase 2 |
| momelotinib | Phase 2 |
| pacritinib | Phase 2 |
| polatuzumab vedotin | Phase 1/Phase 2 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (9)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
80
Total value held
$119.7M
| Holder | Shares | Value |
|---|---|---|
| commodore capital lp | 1,950,000 | $10.9M |
| ra capital management, l.p. | 1,917,354 | $10.7M |
| adage capital partners gp, l.l.c. | 1,806,322 | $10.1M |
| vanguard capital management llc | 1,479,490 | $8.2M |
| susquehanna international group, llp | 1,315,038 | $7.3M |
| caption management, llc | 1,181,900 | $6.6M |
| avidity partners management lp | 927,482 | $6.4M |
| goldman sachs group inc | 947,579 | $5.3M |
| boothbay fund management, llc | 750,410 | $4.2M |
| squadron capital management llc | 750,000 | $4.2M |
Showing top 10 of 80 institutional holders of Karyopharm Therapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Karyopharm Therapeutics Inc.'s pipeline?
Karyopharm Therapeutics Inc. (KPTI) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Karyopharm Therapeutics Inc.'s lead drug candidate?
Karyopharm Therapeutics Inc.'s most advanced tracked candidate is belantamab mafodotin (Phase 1/Phase 2) for Multiple Myeloma.
What is Karyopharm Therapeutics Inc.'s next catalyst?
Karyopharm Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenan" — expected January 1, 2028.
What is Karyopharm Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Karyopharm Therapeutics Inc. has approximately 13.4 months of cash runway.
What is Karyopharm Therapeutics Inc.'s market capitalization?
Karyopharm Therapeutics Inc.'s market capitalization is approximately $213.0M.
Get the full picture on Karyopharm Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.